መነሻ › ስቴቶቲክ የጉበት በሽታ › ሉዊዚያና
በሉዊዚያና ለስቴቶቲክ የጉበት በሽታ የሚደረጉ ክሊኒካዊ ጥናቶች
ለስቴቶቲክ የጉበት በሽታ የሚደረጉ 11 ጥናቶች በሉዊዚያና ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በሉዊዚያና ውስጥ ያሉ ከተሞች
Official study text (English)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Lafayette
- 89bio Clinical Study Site, Lake Charles
- 89bio Clinical Study Site, West Monroe
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Covington
- 89bio Clinical Study Site, Houma
- 89bio Clinical Study Site, Lake Charles
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT06318169A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Tandem Clinical Research, Plaza II, Metairie
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT07527910A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Tandem Clinical Research, Metairie
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Delta Research Partners of Bastrop, LLC, Bastrop
- Tandem Clinical Research, Marrero
- Care Access - New Iberia, New Iberia
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Bastrop
- Akero Clinical Study Site, Covington
- Akero Clinical Study Site, Houma
- እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Marrero
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Tandem Clinical Research, Covington
- Tandem Clinical Research, Houma
- Tandem Clinical Research GI, LLC, Marrero
- እና 4 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Marrero
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ3 ኦገስ 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Bastrop
- GSK Investigational Site, Marrero
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ27 ጁላይ 2026 · NCT07221227A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Tandem Clinical Research, Marrero
ተሳታዮችን በመፈለግ ላይደረጃ 1/2ጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ16 ኤፕሪ 2026 · NCT05648214ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።